Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:01
10/13/16
10/13
07:01
10/13/16
07:01

Ocular Therapeutix announces strategic collaboration agreement with Regeneron

Ocular Therapeutix (OCUL) announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals, Inc. (REGN). Ocular and Regeneron will collaborate on the development of a sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. This formulation is currently in preclinical development. Regeneron's aflibercept is currently approved by the U.S. Food and Drug Administration for certain indications under the brand name EYLEA. Under the terms of the agreement, Ocular Therapeutix and Regeneron will aim to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development. Regeneron has the option to obtain an exclusive license to use Ocular Therapeutix's hydrogel-based technology for the development and commercialization of a sustained release formulation of aflibercept and other biologics targeting VEGF for ophthalmic indications. Ocular Therapeutix will retain all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases. Upon exercising of the option, Ocular Therapeutix would receive a payment of $10 million from Regeneron and Ocular Therapeutix would be responsible for funding development through Phase 1. Regeneron would be responsible for any subsequent development and commercialization costs. Ocular Therapeutix would be eligible to receive up to $305 million in milestone payments from Regeneron for a sustained release version of aflibercept containing Ocular Therapeutix's sustained release hydrogel depot, comprised of up to $155 million in development and regulatory milestone payments, $100 million for the first commercial sale and up to $50 million in commercial milestone payments. In addition, Ocular Therapeutix is eligible to receive tiered high single-digit to low-to-mid teen-digit royalties on potential future net sales.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

SIX

Six Flags

$61.65

-0.14 (-0.23%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Hot Stocks
Six Flags signs agreement to build Six Flags-branded parks at second China site »

Six Flags Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

INOV

Inovalon

$11.30

-0.45 (-3.83%)

07:01
02/21/17
02/21
07:01
02/21/17
07:01
Recommendations
Inovalon analyst commentary  »

Piper sees lawsuit as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SRPT

Sarepta

$28.28

0.31 (1.11%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Hot Stocks
Sarepta agrees to sale of priority review voucher for $125M »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

SEAS

SeaWorld

$19.21

-0.03 (-0.16%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Earnings
Breaking Earnings news story on SeaWorld »

SeaWorld reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TVPT

Travelport

$14.14

-0.06 (-0.42%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Travelport reports Q4 adjusted EPS 23c, consensus 20c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

MDT

Medtronic

$78.88

0.89 (1.14%)

06:58
02/21/17
02/21
06:58
02/21/17
06:58
Earnings
Medtronic reports Q3 EPS $1.12, consensus $1.11 »

Reports Q3 revenue $7.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 27

    Feb

  • 07

    Mar

  • 17

    Mar

  • 21

    Mar

REXR

Rexford Industrial

$22.92

0.24 (1.06%)

06:57
02/21/17
02/21
06:57
02/21/17
06:57
Hot Stocks
Rexford Industrial acquires industrial property in Los Angeles for $17.1M »

Rexford Industrial Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOXO

Loxo Oncology

$41.74

0.36 (0.87%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Hot Stocks
Loxo Oncology completes enrollment for larotrectinib NDA »

Loxo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$30.37

-0.08 (-0.26%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Periodicals
GE succession plan near top of investors' minds, WSJ says »

General Electric CEO Jeff…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Apr

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

06:56
02/21/17
02/21
06:56
02/21/17
06:56
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVN

Trevena

$7.13

0.1 (1.42%)

06:55
02/21/17
02/21
06:55
02/21/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Trevena »

Trevena trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 21

    Mar

TIF

Tiffany

$86.18

3.17 (3.82%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Tiffany, JANA Partners announce agreement to appoint 3 new independent directors »

Tiffany and JANA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:54
02/21/17
02/21
06:54
02/21/17
06:54
Hot Stocks
Breaking Hot Stocks news story on Enable Midstream »

Enable Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ENBL

Enable Midstream

$16.73

0.11 (0.66%)

06:53
02/21/17
02/21
06:53
02/21/17
06:53
Earnings
Enable Midstream reports Q4 EPS 14c, consensus 18c »

Reports Q4 revenue $614M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WLK

Westlake Chemical

$61.66

-0.99 (-1.58%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Earnings
Westlake Chemical reports Q4 EPS 76c with items, consensus 80c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

JNCE

Jounce Therapeutics

$19.90

0.24 (1.22%)

06:51
02/21/17
02/21
06:51
02/21/17
06:51
Initiation
Jounce Therapeutics initiated  »

Jounce Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$29.48

0.48 (1.66%)

06:50
02/21/17
02/21
06:50
02/21/17
06:50
Initiation
JELD-WEN Holding initiated  »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDR

EdR

$40.69

-0.06 (-0.15%)

06:48
02/21/17
02/21
06:48
02/21/17
06:48
Earnings
EdR reaffirms FY17 EPS view 66c-76c, consensus 63c »

Sees FY17 core FFO per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HURN

Huron

$42.60

-4 (-8.58%)

06:48
02/21/17
02/21
06:48
02/21/17
06:48
Downgrade
Huron rating change  »

Huron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

EDR

EdR

$40.69

-0.06 (-0.15%)

06:47
02/21/17
02/21
06:47
02/21/17
06:47
Earnings
EdR reports Q4 EPS 19c, consensus 23c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

MCO

Moody's

$112.90

2.68 (2.43%)

06:45
02/21/17
02/21
06:45
02/21/17
06:45
Downgrade
Moody's rating change  »

Moody's downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

  • 05

    Mar

RIC

Richmont Mines

$9.30

-0.2 (-2.11%)

06:45
02/21/17
02/21
06:45
02/21/17
06:45
Earnings
Richmont Mines reports Q4 EPS 1c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LMOS

Lumos Networks

$15.23

0.09 (0.59%)

, ZAYO

Zayo Group

$30.83

-0.16 (-0.52%)

06:41
02/21/17
02/21
06:41
02/21/17
06:41
Downgrade
Lumos Networks, Zayo Group, GTT Communications rating change  »

Lumos Networks downgraded…

LMOS

Lumos Networks

$15.23

0.09 (0.59%)

ZAYO

Zayo Group

$30.83

-0.16 (-0.52%)

GTT

GTT Communications

$29.00

-0.05 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AER

AerCap

$46.65

-0.14 (-0.30%)

06:41
02/21/17
02/21
06:41
02/21/17
06:41
Hot Stocks
AerCap approves $350M share repurchase program »

Company authorized a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$11.80

0.79 (7.18%)

06:40
02/21/17
02/21
06:40
02/21/17
06:40
Initiation
Miragen Therapeutics initiated  »

Miragen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.